News

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...
TipRanks on MSN12h

Regeneron says FDA delayed review of two Eylea HD submissions

Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea ...

WuXi Biologics, a Chinese CRDMO With Global Revenue, Holds Well During Geopolitical Uncertainties

WuXi has a wide range of technical platforms for state-of-the-art biologic innovations, including the bispecific and multispecific antibodies platform under WuXiBody, the Chinese hamster ovary ...